An employee shows a bottle of the immune drug Areima (camrelizumab) which has been developed for the treatment of nasopharyngeal and esophageal cancer and launched into production at the Petrovax plant, in Moscow region, Russia.21.05.2026#9170486
An employee shows a bottle and packaging of the immune drug Areima (camrelizumab) which has been developed for the treatment of nasopharyngeal and esophageal cancer and launched into production at the Petrovax plant, in Moscow region, Russia.21.05.2026#9170485
A view shows a bottle and packaging of the immune drug Areima (camrelizumab) which has been developed for the treatment of nasopharyngeal and esophageal cancer and launched into production at the Petrovax plant, in Moscow region, Russia.21.05.2026#9170484
A view shows a bottle and packaging of the immune drug Areima (camrelizumab) which has been developed for the treatment of nasopharyngeal and esophageal cancer and launched into production at the Petrovax plant, in Moscow region, Russia.21.05.2026#9170482
Employees work on the production line for the immune drug Areima (camrelizumab) which has been developed for the treatment of nasopharyngeal and esophageal cancer, at the Petrovax plant, in Moscow region, Russia.21.05.2026#9170479
An employee works on the production line for the immune drug Areima (camrelizumab) which has been developed for the treatment of nasopharyngeal and esophageal cancer, at the Petrovax plant, in Moscow region, Russia.21.05.2026#9170478
An employee works on the production line for the immune drug Areima (camrelizumab) which has been developed for the treatment of nasopharyngeal and esophageal cancer, at the Petrovax plant, in Moscow region, Russia.21.05.2026#9170477
A view shows the production line for the immune drug Areima (camrelizumab) which has been developed for the treatment of nasopharyngeal and esophageal cancer, at the Petrovax plant, in Moscow region, Russia.21.05.2026#9170475
A view shows the production line for the immune drug Areima (camrelizumab) which has been developed for the treatment of nasopharyngeal and esophageal cancer, at the Petrovax plant, in Moscow region, Russia.21.05.2026#9170474
An employee works on the production line for the immune drug Areima (camrelizumab) which has been developed for the treatment of nasopharyngeal and esophageal cancer, at the Petrovax plant, in Moscow region, Russia.21.05.2026#9170472
A view shows the production line for the immune drug Areima (camrelizumab) which has been developed for the treatment of nasopharyngeal and esophageal cancer, at the Petrovax plant, in Moscow region, Russia.21.05.2026#9170471
An employee works on the production line for the immune drug Areima (camrelizumab) which has been developed for the treatment of nasopharyngeal and esophageal cancer, at the Petrovax plant, in Moscow region, Russia.21.05.2026#9170470
A view shows the production line for the immune drug Areima (camrelizumab) which has been developed for the treatment of nasopharyngeal and esophageal cancer, at the Petrovax plant, in Moscow region, Russia.21.05.2026#9170469
An employee works on the production line for the immune drug Areima (camrelizumab) which has been developed for the treatment of nasopharyngeal and esophageal cancer, at the Petrovax plant, in Moscow region, Russia.21.05.2026#9170466
